Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uproleselan in COVID-19 Pneumonia
NCT05057221Phase 2Terminated
- Start
- Nov 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of uproleselan in COVID-19 pneumonia. Started Nov 2021; status: terminated.
02
Drugs
uproleselan
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT05057221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057221.